levodopa has been researched along with ubiquinone in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reed, JD; Schneider, EL | 1 |
| Dirr, A; Gerlach, M; Gerstner, A; Götz, ME; Harth, R; Janetzky, B; Kuhn, W; Riederer, P | 1 |
| Olanow, CW; Schapira, AH | 1 |
| Arlt, S; Beisiegel, U; Buhmann, C; Kontush, A; Möller-Bertram, T; Oechsner, M; Sperber, S; Stuerenburg, HJ | 1 |
| Fahn, S | 1 |
| Levine, J; Lieberman, A; Lyons, K; Myerburg, R | 1 |
| Jankovic, J; Olanow, CW | 1 |
| Durner, J; Fuchs, G; Greulich, W; Henningsen, H; Herting, B; Jost, WH; Koch, R; Kuhn, W; Kupsch, A; Müller, T; Niklowitz, P; Oertel, WH; Reichmann, H; Spiegel, J; Storch, A; Vieregge, P | 1 |
| Abdin, AA; Hamouda, HE | 1 |
| Hauser, RA | 1 |
| Belcastro, V; Caccamo, D; Calabresi, P; Currò, M; Ferlazzo, N; Gorgone, G; Ientile, R; Parisi, G; Parnetti, L; Pisani, F; Rossi, A; Tambasco, N | 1 |
| Attia, HN; Maklad, YA | 1 |
5 review(s) available for levodopa and ubiquinone
| Article | Year |
|---|---|
Life extension.
Topics: Aged; Aging; Animals; Antioxidants; Dehydroepiandrosterone; Diet; Energy Intake; Ethics, Medical; Female; Free Radicals; Humans; Hypophysectomy; Immunocompetence; Levodopa; Life Expectancy; Longevity; Male; Meclofenoxate; Mice; Middle Aged; Models, Biological; Physical Exertion; Procaine; Superoxide Dismutase; Ubiquinone | 1985 |
Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.
Topics: Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Coenzymes; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Ubiquinone | 2004 |
ALS lessons learned from other neurological diseases. Parkinson's disease.
Topics: Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Behavioral Symptoms; Coenzymes; Controlled Clinical Trials as Topic; Disease Progression; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Ubiquinone | 2004 |
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Coenzymes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Membrane Proteins; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Ubiquinone; Vitamin E | 2005 |
Early pharmacologic treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Early Diagnosis; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Ubiquinone; Vitamin E | 2010 |
1 trial(s) available for levodopa and ubiquinone
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
Topics: Adult; Aged; Antioxidants; Cell Respiration; Coenzymes; Dopamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Energy Metabolism; Female; Humans; Levodopa; Male; Middle Aged; Neurons; Oxidative Stress; Parkinson Disease; Placebos; Substantia Nigra; Treatment Outcome; Ubiquinone; Vitamins | 2007 |
6 other study(ies) available for levodopa and ubiquinone
| Article | Year |
|---|---|
Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antioxidants; Antiparkinson Agents; Biomarkers; Blood Platelets; Coenzymes; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Oxidation-Reduction; Parkinson Disease; Selegiline; Ubiquinone | 2000 |
Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication.
Topics: Adult; alpha-Tocopherol; Antioxidants; Antiparkinson Agents; Ascorbic Acid; Biomarkers; Brain; Dopamine; Female; Humans; Levodopa; Lipoproteins; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Reference Values; Sulfhydryl Compounds; Ubiquinone; Up-Regulation | 2004 |
Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Ubiquinone | 2005 |
Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Levodopa; Mitochondria; NAD; Neurons; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Psychomotor Performance; Rats; Rotenone; Spectrophotometry; Ubiquinone; Ultrasonography; Vitamins | 2008 |
Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; Ubiquinone; Vitamin B 12 | 2012 |
Neuroprotective effects of coenzyme Q10 on paraquat-induced Parkinson's disease in experimental animals.
Topics: Animals; Disease Models, Animal; Levodopa; Male; Mice; Mitochondria; Neurons; Neuroprotective Agents; Oxidative Stress; Paraquat; Parkinson Disease; Protein Carbonylation; Ubiquinone | 2018 |